FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384828120> ?p ?o ?g. }

• W4384828120 abstract "<p>Metronomic topotecan treatment as a single agent and in combination with DTX reduces EMT/stemness in AR^Low/mCRPC/NEPC clonally derived taxane-resistant prostate cancer subtypes. <b>A,</b> Assessment of posttreated “stem-like” cells (CD44^high/CD133^high) population in taxane-resistant AR^Low/mCRPC cell lines by Flow cytometry: DUTXR cells line stained with stemness markers (CD44, CD33, and both CD44/133) after CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments. CONV-TOPO, METRO-TOPO, and combination (CONV-DTX+METRO-TOPO) treatments reduced CD44^high cells 81.0%, 71.5%, and 63.4%, respectively, in taxane-resistant AR^Low mCRPC DUTXR cells. Therefore, METRO-TOPO as single agent and in combination treatment reduced the highest percentage of “stem like” cell population load (<i>P</i> < 0.05; <a href=#tbl2 target=_blank>Table 2</a>). <b>B,</b> Colony-forming assay: Number and size of colonies were reduced after all treatments compared with control (no-drug treatment). Next, combination treatment with CONV-DTX+METRO-TOPO reduced the number and size of colonies the greatest compared with CONV-TOPO, CONV-DTX, and METRO-TOPO treatments in the DUTXR cell line. Posttreatment colony number and size reduction in the following order: CONV-TOPO>CONV-DTX>METRO-TOPO>Combination (METRO-TOPO+CONV-DTX). Therefore, METRO-TOPO as a single agent or in combination reduced highest number of the colony and size compared with other treatments. Colonies were developed for 21 days (*, <i>P</i> ≤ 0.05). <b>C,</b> Immunoblot analysis: Proteins representing top EMT markers were downregulated significantly after METRO-TOPO treatment compared with CONV-TOPO treatment in AR^Low/mCSPC/NEPC^{taxane-resistant} (DUTXR) prostate cancer cell lines. Combination treatment (CONV-DTX+METRO-TOPO) exhibited the highest downregulation of EMT marker proteins compared with other treatments. Posttreatment protein expression downregulation was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. Beta-actin was used as a control housekeeping gene (*, <i>P</i> ≤ 0.05). <b>D,</b> Assessment of treatment effect on “stem-like” cells (CD44^high) population in taxane-resistant AR^Low/mCRPC cell lines by FACS: DUTXR cell line stained with stemness markers (CD44) and sorted CD44⁺ versus CD44⁻ cells, followed by CONV-TOPO, METRO-TOPO, CONV-DTX, and combination (CONV-DTX+METRO-TOPO) treatments. Next, cell cytotoxicity (MTT) and caspase 3/7 activity (apoptosis) were assessed. (<b>I</b>) Cytotoxicity profiling by MTT showed that combination (CONV-DTX+METRO-TOPO) treatment reduced highest cell survival or cell growth compared with other treatments. Posttreatment cell survival or cell growth reduction was following orders: CONV-TOPO>CONV-DTX>METRO-TOPO. (<b>II</b>) Combination (CONV-DTX+METRO-TOPO) treatment induced greater apoptosis compared with other treatments in taxane-resistant AR^Low/mCRPC-DUTXR cell lines. (<b>III</b> and <b>IV</b>) CD44⁻ cells showed no significant differences for all treatments (*, <i>P</i> ≤ 0.05). <b>E,</b> Pretreatment and posttreatment microscope imaging: Results showed significantly higher cell death in METRO-TOPO and combination (CONV-DTX+METRO-TOPO) treatments compared with CONV treatment for both the drugs (TOPO and DTX). Images were captured by Cytation5 Cell Imaging Multimode Reader at a 1,000 μm scale. ImageJ analysis showed a significant difference in cell density for CONV versus METRO versus combination TOPO treatments (*, <i>P</i> ≤ 0.05).</p>" @default.
• W4384828120 created "2023-07-21" @default.
• W4384828120 creator A5001324574 @default.
• W4384828120 creator A5008531944 @default.
• W4384828120 creator A5011515014 @default.
• W4384828120 creator A5017626381 @default.
• W4384828120 creator A5018701434 @default.
• W4384828120 creator A5027205659 @default.
• W4384828120 creator A5033280065 @default.
• W4384828120 creator A5037592204 @default.
• W4384828120 creator A5045972335 @default.
• W4384828120 creator A5052820201 @default.
• W4384828120 creator A5060515951 @default.
• W4384828120 creator A5071817275 @default.
• W4384828120 creator A5074079824 @default.
• W4384828120 creator A5075033462 @default.
• W4384828120 creator A5086930277 @default.
• W4384828120 creator A5092076789 @default.
• W4384828120 date "2023-07-19" @default.
• W4384828120 modified "2023-09-25" @default.
• W4384828120 title "FIGURE 6 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers" @default.
• W4384828120 doi "https://doi.org/10.1158/2767-9764.23709936" @default.
• W4384828120 hasPublicationYear "2023" @default.
• W4384828120 type Work @default.
• W4384828120 citedByCount "0" @default.
• W4384828120 crossrefType "posted-content" @default.
• W4384828120 hasAuthorship W4384828120A5001324574 @default.
• W4384828120 hasAuthorship W4384828120A5008531944 @default.
• W4384828120 hasAuthorship W4384828120A5011515014 @default.
• W4384828120 hasAuthorship W4384828120A5017626381 @default.
• W4384828120 hasAuthorship W4384828120A5018701434 @default.
• W4384828120 hasAuthorship W4384828120A5027205659 @default.
• W4384828120 hasAuthorship W4384828120A5033280065 @default.
• W4384828120 hasAuthorship W4384828120A5037592204 @default.
• W4384828120 hasAuthorship W4384828120A5045972335 @default.
• W4384828120 hasAuthorship W4384828120A5052820201 @default.
• W4384828120 hasAuthorship W4384828120A5060515951 @default.
• W4384828120 hasAuthorship W4384828120A5071817275 @default.
• W4384828120 hasAuthorship W4384828120A5074079824 @default.
• W4384828120 hasAuthorship W4384828120A5075033462 @default.
• W4384828120 hasAuthorship W4384828120A5086930277 @default.
• W4384828120 hasAuthorship W4384828120A5092076789 @default.
• W4384828120 hasBestOaLocation W43848281201 @default.
• W4384828120 hasConcept C121608353 @default.
• W4384828120 hasConcept C126322002 @default.
• W4384828120 hasConcept C1491633281 @default.
• W4384828120 hasConcept C153911025 @default.
• W4384828120 hasConcept C185592680 @default.
• W4384828120 hasConcept C2777511904 @default.
• W4384828120 hasConcept C2780932548 @default.
• W4384828120 hasConcept C2781190966 @default.
• W4384828120 hasConcept C2908647359 @default.
• W4384828120 hasConcept C502942594 @default.
• W4384828120 hasConcept C530470458 @default.
• W4384828120 hasConcept C54355233 @default.
• W4384828120 hasConcept C553184892 @default.
• W4384828120 hasConcept C55493867 @default.
• W4384828120 hasConcept C71924100 @default.
• W4384828120 hasConcept C81885089 @default.
• W4384828120 hasConcept C86803240 @default.
• W4384828120 hasConcept C99454951 @default.
• W4384828120 hasConceptScore W4384828120C121608353 @default.
• W4384828120 hasConceptScore W4384828120C126322002 @default.
• W4384828120 hasConceptScore W4384828120C1491633281 @default.
• W4384828120 hasConceptScore W4384828120C153911025 @default.
• W4384828120 hasConceptScore W4384828120C185592680 @default.
• W4384828120 hasConceptScore W4384828120C2777511904 @default.
• W4384828120 hasConceptScore W4384828120C2780932548 @default.
• W4384828120 hasConceptScore W4384828120C2781190966 @default.
• W4384828120 hasConceptScore W4384828120C2908647359 @default.
• W4384828120 hasConceptScore W4384828120C502942594 @default.
• W4384828120 hasConceptScore W4384828120C530470458 @default.
• W4384828120 hasConceptScore W4384828120C54355233 @default.
• W4384828120 hasConceptScore W4384828120C553184892 @default.
• W4384828120 hasConceptScore W4384828120C55493867 @default.
• W4384828120 hasConceptScore W4384828120C71924100 @default.
• W4384828120 hasConceptScore W4384828120C81885089 @default.
• W4384828120 hasConceptScore W4384828120C86803240 @default.
• W4384828120 hasConceptScore W4384828120C99454951 @default.
• W4384828120 hasLocation W43848281201 @default.
• W4384828120 hasLocation W43848281202 @default.
• W4384828120 hasOpenAccess W4384828120 @default.
• W4384828120 hasPrimaryLocation W43848281201 @default.
• W4384828120 hasRelatedWork W1975820693 @default.
• W4384828120 hasRelatedWork W2067939746 @default.
• W4384828120 hasRelatedWork W2144439788 @default.
• W4384828120 hasRelatedWork W2374430045 @default.
• W4384828120 hasRelatedWork W2430827979 @default.
• W4384828120 hasRelatedWork W2509022872 @default.
• W4384828120 hasRelatedWork W2513994891 @default.
• W4384828120 hasRelatedWork W2748952813 @default.
• W4384828120 hasRelatedWork W2899084033 @default.
• W4384828120 hasRelatedWork W4362609019 @default.
• W4384828120 isParatext "false" @default.
• W4384828120 isRetracted "false" @default.
• W4384828120 workType "article" @default.